MEI Pharma, Inc. (MEIP) Forms $2.18 Double Bottom; BLACKPEARL RESOURCES ORDINARY SHARE (BLKPF) Shorts Lowered By 85.71%

BLACKPEARL RESOURCES INC ORDINARY SHARE (OTCMKTS:BLKPF) had a decrease of 85.71% in short interest. BLKPF’s SI was 3,000 shares in April as released by FINRA. Its down 85.71% from 21,000 shares previously. With 300 avg volume, 10 days are for BLACKPEARL RESOURCES INC ORDINARY SHARE (OTCMKTS:BLKPF)’s short sellers to cover BLKPF’s short positions. It closed at $1.05 lastly. It is down 0.00% since April 20, 2017 and is . It has underperformed by 11.55% the S&P500.

MEI Pharma, Inc. (MEIP) formed double bottom with $2.11 target or 3.00% below today’s $2.18 share price. MEI Pharma, Inc. (MEIP) has $80.77 million valuation. The stock increased 0.46% or $0.01 during the last trading session, reaching $2.18. About 10,796 shares traded. MEI Pharma, Inc. (NASDAQ:MEIP) has risen 32.91% since April 20, 2017 and is uptrending. It has outperformed by 21.36% the S&P500.

BlackPearl Resources Inc. engages in the acquisition, exploration, development, and production of heavy crude oil, bitumen, and natural gas in Canada. The company has market cap of $332.92 million. The Company’s principal properties include the Mooney oil property with an area of approximately 39,680 acres located in north-central Alberta; the Blackrod oil sands project with oil sand leases and permits covering an area of approximately 42,880 acres situated in the Blackrod area of northern Alberta; and the Onion Lake oil property with an area of approximately 8,094 net acres located in Saskatchewan. It has a 27.63 P/E ratio. The firm was formerly known as Pearl Exploration and Production Ltd. and changed its name to BlackPearl Resources Inc. in May 2009.

Among 4 analysts covering MEI Pharma (NASDAQ:MEIP), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. MEI Pharma had 8 analyst reports since September 4, 2015 according to SRatingsIntel. On Wednesday, September 6 the stock rating was maintained by Stifel Nicolaus with “Hold”. The company was maintained on Wednesday, August 2 by Oppenheimer. The stock of MEI Pharma, Inc. (NASDAQ:MEIP) earned “Buy” rating by Oppenheimer on Wednesday, June 14. The stock of MEI Pharma, Inc. (NASDAQ:MEIP) has “Buy” rating given on Monday, June 26 by Oppenheimer. Wedbush maintained MEI Pharma, Inc. (NASDAQ:MEIP) on Friday, September 4 with “Hold” rating. The firm has “Buy” rating by Oppenheimer given on Wednesday, May 31.

Analysts await MEI Pharma, Inc. (NASDAQ:MEIP) to report earnings on May, 3. They expect $-0.27 EPS, down 1,250.00% or $0.25 from last year’s $-0.02 per share. After $-0.16 actual EPS reported by MEI Pharma, Inc. for the previous quarter, Wall Street now forecasts 68.75% negative EPS growth.

MEI Pharma, Inc. (NASDAQ:MEIP) Institutional Positions Chart